BAKER BROS. ADVISORS LP Q2 2017 Filing
Filed August 14, 2017
Portfolio Value
$11.4B
Holdings
120
Report Date
Q2 2017
Filing Type
13F-HR
All Holdings (120 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 34,130,161 | $4.3T | 37569.23% | |
| 2 | SGENEURSeattle Genetics, Inc. | 45,725,556 | $2.4T | 20683.27% | |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | 8,553,864 | $1.0T | 9098.71% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 25,819,768 | $720.1B | 6295.56% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 5,905,673 | $536.4B | 4689.05% | |
| 6 | —Genomic Health, Inc. | 13,779,866 | $448.5B | 3921.30% | |
| 7 | —DBV Technologies S.A. | 5,509,560 | $196.7B | 1720.04% | |
| 8 | ONCBeiGene, Ltd. | 3,673,175 | $165.3B | 1445.07% | |
| 9 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $153.8B | 1344.98% | |
| 10 | —Achaogen, Inc. | 4,804,604 | $104.4B | 912.75% | |
| 11 | AMRNAmarin Corporation plc | 22,669,509 | $91.4B | 798.69% | |
| 12 | —Advanced Accelerator Applications S.A. | 2,221,706 | $86.7B | 758.28% | |
| 13 | —Spark Therapeutics, Inc. | 1,318,341 | $78.8B | 688.54% | |
| 14 | NVTA1EURInvitae Corporation | 7,288,300 | $69.7B | 609.14% | |
| 15 | BCRXBioCryst Pharmaceuticals, Inc. | 11,716,784 | $65.1B | 569.53% | |
| 16 | —Bellicum Pharmaceuticals, Inc. | 5,032,313 | $58.8B | 513.86% | |
| 17 | —AveXis, Inc. | 625,000 | $51.4B | 448.93% | |
| 18 | EX9Exelixis, Inc. | 2,082,012 | $51.3B | 448.31% | |
| 19 | ASNDAscendis Pharma A/S | 1,751,463 | $48.6B | 425.07% | |
| 20 | NVAX 3.75 02/01/23Novavax, Inc. | 108,500,000 | $46.4B | 405.90% | |
| 21 | HRTXHeron Therapeutics, Inc. | 2,783,569 | $38.6B | 337.04% | |
| 22 | GBYSangamo Therapeutics, Inc. | 4,113,376 | $36.2B | 316.46% | |
| 23 | —bluebird bio, Inc. | 301,441 | $31.7B | 276.84% | |
| 24 | —Acorda Therapeutics, Inc. | 35,083,000 | $30.0B | 262.14% | |
| 25 | —Versartis, Inc. | 1,660,593 | $29.0B | 253.33% | |
| 26 | NBIXNeurocrine Biosciences, Inc. | 616,682 | $28.4B | 248.00% | |
| 27 | CERSCerus Corporation | 10,241,943 | $25.7B | 224.74% | |
| 28 | IMGNEURImmunoGen, Inc. | 3,015,353 | $21.4B | 187.43% | |
| 29 | —Progenics Pharmaceuticals, Inc. | 3,150,808 | $21.4B | 187.04% | |
| 30 | HALOHalozyme Therapeutics, Inc. | 1,581,424 | $20.3B | 177.24% | |
| 31 | GLPGGalapagos NV | 259,894 | $19.9B | 173.86% | |
| 32 | XNCRXencor, Inc. | 872,072 | $18.4B | 160.94% | |
| 33 | MRUSMerus N.V. | 1,160,014 | $18.4B | 160.74% | |
| 34 | —Idera Pharmaceuticals, Inc. | 10,294,970 | $17.7B | 154.80% | |
| 35 | —NeuroDerm Ltd. | 571,667 | $17.1B | 149.43% | |
| 36 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $17.0B | 148.57% | |
| 37 | SG7Sage Therapeutics, Inc. | 208,328 | $16.6B | 145.05% | |
| 38 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $15.7B | 137.53% | |
| 39 | —La Jolla Pharmaceutical Company | 504,732 | $15.0B | 131.36% | |
| 40 | CPRXCatalyst Pharmaceuticals, Inc. | 5,102,153 | $14.1B | 123.11% | |
| 41 | —Aimmune Therapeutics, Inc. | 673,908 | $13.9B | 121.14% | |
| 42 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.5B | 118.43% | |
| 43 | ARRYEURArray BioPharma Inc. | 1,585,913 | $13.3B | 116.05% | |
| 44 | —Aegerion Pharmaceuticals, Inc. | 14,517,000 | $11.5B | 100.97% | |
| 45 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $11.4B | 100.06% | |
| 46 | —Loxo Oncology, Inc. | 138,312 | $11.1B | 96.96% | |
| 47 | —Abeona Therapeutics Inc. | 1,684,364 | $10.8B | 94.24% | |
| 48 | —Ignyta, Inc. | 896,000 | $9.3B | 81.08% | |
| 49 | —Syros Pharmaceuticals, Inc. | 574,835 | $9.2B | 80.86% | |
| 50 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $8.9B | 77.89% | |
| 51 | ALKSAlkermes plc | 150,251 | $8.7B | 76.15% | |
| 52 | —Achillion Pharmaceuticals, Inc. | 1,856,637 | $8.5B | 74.50% | |
| 53 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $8.3B | 72.41% | |
| 54 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $7.6B | 66.15% | |
| 55 | CBAYUSDCymaBay Therapeutics, Inc. | 1,291,775 | $7.4B | 65.05% | |
| 56 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,518,882 | $6.9B | 60.12% | |
| 57 | IM8NInsmed Incorporated | 400,000 | $6.9B | 60.01% | |
| 58 | AGIOAgios Pharmaceuticals, Inc. | 128,666 | $6.6B | 57.88% | |
| 59 | MGNXMacroGenics, Inc. | 363,676 | $6.4B | 55.67% | |
| 60 | GLYCEURGlycoMimetics, Inc. | 563,312 | $6.3B | 54.96% | |
| 61 | —ContraFect Corporation | 4,045,876 | $5.9B | 51.29% | |
| 62 | —Stemline Therapeutics, Inc. | 633,497 | $5.8B | 50.95% | |
| 63 | SELBUSDSelecta Biosciences, Inc. | 289,809 | $5.8B | 50.32% | |
| 64 | ASMBAssembly Biosciences, Inc. | 250,000 | $5.2B | 45.14% | |
| 65 | —Spring Bank Pharmaceuticals, Inc. | 373,144 | $5.1B | 44.17% | |
| 66 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,137,872 | $4.4B | 38.30% | |
| 67 | BDQMAlbireo Pharma, Inc. | 200,000 | $4.1B | 36.02% | |
| 68 | —Array BioPharma Inc. | 3,000,000 | $4.1B | 35.55% | |
| 69 | —NewLink Genetics Corporation | 500,000 | $3.7B | 32.13% | |
| 70 | —Nabriva Therapeutics plc | 350,000 | $3.7B | 32.07% | |
| 71 | —Epizyme, Inc. | 232,481 | $3.5B | 30.69% | |
| 72 | OVIDOvid Therapeutics Inc. | 333,333 | $3.5B | 30.57% | |
| 73 | —Ra Pharmaceuticals, Inc. | 177,952 | $3.3B | 29.16% | |
| 74 | —Adamas Pharmaceuticals, Inc. | 172,630 | $3.0B | 26.39% | |
| 75 | —Inotek Pharmaceuticals Corporation | 5,000,000 | $3.0B | 26.04% | |
| 76 | ANABAnaptysBio, Inc. | 117,211 | $2.8B | 24.52% | |
| 77 | —Zogenix, Inc. | 185,290 | $2.7B | 23.49% | |
| 78 | —Protalix BioTherapeutics, Inc. | 3,423,000 | $2.6B | 22.49% | |
| 79 | —Alder BioPharmaceuticals, Inc. | 217,328 | $2.5B | 21.75% | |
| 80 | NTRANatera, Inc. | 228,676 | $2.5B | 21.71% | |
| 81 | NVAXNovavax, Inc. | 2,000,000 | $2.3B | 20.11% | |
| 82 | —Akari Therapeutics plc | 496,901 | $2.3B | 20.03% | |
| 83 | —Tonix Pharmaceuticals Holding Corp. | 510,922 | $2.2B | 19.34% | |
| 84 | —Trevena, Inc. | 950,000 | $2.2B | 19.10% | |
| 85 | —Aevi Genomic Medicine, Inc. | 1,618,089 | $2.2B | 18.81% | |
| 86 | ARGXargenx SE | 100,000 | $2.1B | 18.54% | |
| 87 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $2.0B | 17.50% | |
| 88 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.0B | 17.17% | |
| 89 | TREURTrillium Therapeutics Inc. | 413,697 | $1.8B | 15.91% | |
| 90 | —Dimension Therapeutics, Inc. | 1,251,881 | $1.8B | 15.87% | |
| 91 | RAREUltragenyx Pharmaceutical Inc. | 25,000 | $1.6B | 13.58% | |
| 92 | —MediWound Ltd. | 226,000 | $1.5B | 13.44% | |
| 93 | —Juno Therapeutics, Inc. | 50,000 | $1.5B | 13.07% | |
| 94 | —Immune Design Corp. | 148,937 | $1.5B | 12.69% | |
| 95 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $1.4B | 12.35% | |
| 96 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $1.4B | 12.27% | |
| 97 | —MyoKardia, Inc. | 100,000 | $1.3B | 11.45% | |
| 98 | CLLSCellectis S.A. | 50,000 | $1.3B | 11.29% | |
| 99 | —InVivo Therapeutics Holdings Corp. | 400,000 | $1.1B | 9.44% | |
| 100 | MDGLMadrigal Pharmaceuticals, Inc. | 57,762 | $939.0M | 8.21% |
Page 1 of 2Next